-
1.
公开(公告)号:US20200330459A1
公开(公告)日:2020-10-22
申请号:US16089842
申请日:2017-04-05
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , OSAKA UNIVERSITY
IPC分类号: A61K31/4985 , C12N15/113 , A61K39/395 , A61P9/00 , A61P3/00
摘要: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. The inventors identified osteopontin (OPN) as a critical mediator of adipose tissue remodeling and senescence in obesity and extends this observation to related co-morbidities such as cardiomyopathy. Said result raises the possibility that inhibition of OPN activity may be of value in the prevention of cardiometabolic disease, in particular metabolic cardiomyopathy for which no specific treatment is yet available. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor.
-
公开(公告)号:US20230085651A1
公开(公告)日:2023-03-23
申请号:US17787787
申请日:2020-12-22
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS , UNIVERSITE PAUL SABATIER TOULOUSE III , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE)
发明人: Muriel BLANZAT , Ranime JEBBAWI , Rémy POUPOT , Cédric-Olivier TURRIN , Michel SIMON , Emily CLEMENT , Hélène LABIE , Abdelouahd OUKHRIB
摘要: The present invention relates to sugar-derived catanionic surfactant vesicles comprising anti-inflammatory dendrimers and to their use as a medicament, more particularly in the treatment of psoriasis.
-
公开(公告)号:US20170340591A1
公开(公告)日:2017-11-30
申请号:US15538031
申请日:2015-12-23
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE DE NICE SOPHIA ANTIPOLIS-GRAND CHÂTEAU
CPC分类号: A61K31/197 , A61K31/00 , A61K35/39 , A61K39/00 , A61K45/06 , A61K2039/505 , C07K16/26 , C07K2317/76 , C12N5/0676 , C12N2501/335 , C12N2501/845 , C12N2506/22 , A61K2300/00
摘要: The present invention relates to methods of generating a population of beta cells from a population of alpha cells, by contacting said population of alpha cells with GABA or a GABA receptor agonist, in combination with a monoclonal glucagon neutralizing antibody or other alpha cell mass regulating compounds, for an improved diabetes therapy.
-
公开(公告)号:US20160257710A1
公开(公告)日:2016-09-08
申请号:US15032655
申请日:2014-11-04
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE) , UNIVERSITE DE TOURS FRANCOIS RABELAIS , UNIWERSYTET GDANSKI
发明人: Francis GAUTHIER , Brice KORKMAZ , Adam LESNER
IPC分类号: C07K5/113 , G01N33/573 , C07K5/103 , A61K47/48 , C07K5/117
CPC分类号: C07K5/1021 , A61K38/00 , A61K47/545 , A61K47/60 , C07K5/0808 , C07K5/0819 , C07K5/0823 , C07K5/101 , C07K5/1024 , G01N33/573
摘要: The present invention relates to peptidyl phosphonate esters compounds and their use selective inhibitors of proteinase 3, in particular for treating or diagnosing inflammator autoimmune and cancer disorders. More specifically, the invention concerns nov peptidyl phosphonate esters compounds, including without limitation, compounds with Asp-Tyr-Asp-Ala or Pro-Tyr-Asp-Ala, Pro-Tyr-Asp-Avl, Val-Tyr-Asp-Avl peptide structure or their derivatives.
摘要翻译: 本发明涉及肽基膦酸酯化合物及其使用蛋白酶3的选择性抑制剂,特别是用于治疗或诊断炎症自身免疫和癌症疾病。 更具体地说,本发明涉及Nov肽基膦酸酯化合物,包括但不限于Asp-Tyr-Asp-Ala或Pro-Tyr-Asp-Ala,Pro-Tyr-Asp-Avl,Val-Tyr-Asp-Avl肽 结构或其衍生物。
-
公开(公告)号:US20230034677A1
公开(公告)日:2023-02-02
申请号:US17778617
申请日:2020-11-20
申请人: INSERM (Institut National de la Santé et la Recherche (Médicale) , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris-Est Créteil val de Marne , Baylor Research Institutue , Mabquest
发明人: Yves LEVY , Giuseppe PANTALEO , Craig FENWICK , Sandra ZURAWSKI , Gérard ZURAWSKI , Nabila SEDDIKI
IPC分类号: C07K14/54 , C07K14/715 , A61P35/00
摘要: The inventors now provide novel IL-15/IL-15 receptor alpha (IL-15Rα) fusion proteins. Furthermore, as a complement to anti-PD-1 therapy, the inventors developed a series of anti-PD-1/IL-15/IL-15 receptor alpha (IL-15Rα) immunocytokines that are able to simultaneously target multiple steps in the immune activation process. The development of said immunocytokines provides the potential benefits associated with anti-PD-1 antibodies and IL-15 administered individually with several distinct advantages. These include a significantly extended in vivo half-life relative to the IL-15 therapy, administration of a pre-formed IL-15/IL-15Rα complex that would preclude the need for IL-15Rα trans-presentation, high activity leading to a low target therapeutic dose and targeted delivery of IL-15 to regions with high PD-1 cells that will limit off-target adverse events.
-
公开(公告)号:US20220018828A1
公开(公告)日:2022-01-20
申请号:US17295608
申请日:2019-11-27
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE , UNIVERSITÉ PAUL SABATIER TOULOUSE III
IPC分类号: G01N33/50
摘要: To overcome the difficulty in achieving a quantitative assessment of CTL function in clinical settings, the inventors aimed at developing a new method inspired by their knowledge of the CTL/tumor target biology and based on flow cytometry. In particular, to directly detect the earliest steps of tumor cell resistance to CTL attack at the lytic synapse the inventors developed a method to monitor CTL/tumor cells interaction in the presence of FM1-43, a fluorescent lipophilic dye that rapidly intercalates into lipid bilayer during the membrane turnover that accompanies plasma membrane reparation. This assay allows the inventors to measure reparative membrane turnover of tumor cells under CTL attack by FACS analysis at the whole tumor cell population level. They initially applied this approach to compare the response of melanoma cell (D10 cells) to CTL attack as compared to conventional target cells that are sensitive to CTL mediated cytotoxicity (EB V-transformed B cells, JY cells). The methodology allows to rapidly assessing the synaptic resistance of tumor target cells to CTL attack and the intrinsic capacity of CD8+CTL to efficiently kill their target cells. Thus, the present invention relates to methods and kit for assaying lytic potential of immune effector cells and uses thereof in diagnostic assays.
-
公开(公告)号:US20170137472A1
公开(公告)日:2017-05-18
申请号:US15317196
申请日:2015-06-08
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE , UNIVERSITÉ PAUL SABATIER TOULOUSE III , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) , ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE)
IPC分类号: C07K14/005 , C12N7/00 , A61K38/16
CPC分类号: C07K14/005 , A61K38/162 , C07K2319/07 , C07K2319/10 , C12N7/00 , C12N2740/16322 , C12N2760/00022 , C12N2760/00033
摘要: The present invention relates to methods and compositions for the prevention or treatment of neurodegenerative diseases.
-
-
-
-
-
-